DPYD tests work to identify patients with dihydropyrimidine dehydrogenase deficiency, which can cause them to experience serious adverse reactions to capecitabine or 5-fluorouracil, also known as 5-FU.
Patients with this metabolism deficiency have a risk of serious toxicity higher than 70%, Daniel Hertz, PharmD, PhD, a pharmacy professor at the University of Michigan College of Pharmacy, told the ASHP. 5-FU treatments can be fatal for these patients.
Wentworth-Douglass Hospital in Dover, N.H., reduces starting 5-FU doses by 25% to 50% in an effort to ensure tolerability and safety. Experts said minimizing starting doses of the popular chemotherapy have not affected cancer treatment efficacy.
“If we’re treating 1,000 of these patients every year, we’re bound to find 50-70 patients that could be at risk for very severe toxicity, hospitalizations, and even potentially drug-related fatality by receiving standard dosing,” Jai Patel, PharmD, an associate research director at Charlotte, N.C.-based Levine Cancer Institute, told the ASHP.
Screening patients for DPYD gene variants is the norm in Europe, according to the ASHP, but the American Society of Clinical Oncology and the U.S. National Comprehensive Cancer Network don’t include this practice in their guidelines.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
